Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$9.55 USD
+0.32 (3.47%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $9.54 -0.01 (-0.10%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RCUS 9.55 +0.32(3.47%)
Will RCUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCUS
Pacira (PCRX) Tops Q2 Earnings Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Other News for RCUS
Arcus Biosciences Inc (RCUS) Announces Equity Awards for New Employee | RCUS stock news
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News
Arcus Biosciences (RCUS) Gains FDA Orphan Drug Status for Pancreatic Cancer Treatment
Arcus says Gilead-partnered cancer drug won FDA orphan status
Arcus Biosciences’ cancer drug gets orphan drug status